Zeblong T 40mg/8mg Tablet is a combination antihypertensive medication containing Telmisartan 40mg and Azelnidipine 8mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Azelnidipine is a long-acting dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, promoting vasodilation and reducing peripheral vascular resistance. The synergistic action of these two agents provides effective management of hypertension, improving blood pressure control and reducing the risk of cardiovascular events such as stroke and myocardial infarction. Zeblong T is indicated for patients who require combination therapy for essential hypertension when monotherapy is insufficient. The tablet should be administered orally once daily, with or without food, as prescribed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in pregnancy and lactation. Common adverse effects may include dizziness, headache, peripheral edema, and fatigue. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment to ensure safety and efficacy.